- Comment
- Published:
- Guan-Cheng Lin ORCID: orcid.org/0009-0006-1249-349X1,
- Li-Te Yin1 &
- Kun-Shiang Chen1
Eye (2025)Cite this article
-
Metrics details
Subjects
- Health care
- Medical research
- Risk factors
Buy or subscribe
Myopia is currently one of the major public health issues globally. Holden et al. projected that the global myopic population will reach 4.758 billion by 2050, meaning that approximately half of the world’s population will be myopic [1]. One study indicated that once children develop myopia, East Asians and Caucasians will experience progression rates of −1.00 D and −0.50 D per year, respectively [2]. These findings indicate that slowing the progression of myopia has become a critical modern health concern.
In 2000, the Taiwan Ophthalmological Society recommended using atropine as a myopia treatment tool. Subsequently, the prescription rate of atropine for children aged 4–18 in Taiwan increased from 4.5% in 2000 to 10.3% in 2007, representing a 2.29-fold increase. After nearly 20 years, atropine remains the primary method for controlling myopia [3, 4]. However, despite its long-term and widespread use, the increasing prevalence of myopia in Taiwan suggests that the real-world effectiveness of atropine may be limited by additional factors. Between 1983 and 2017, Taiwan conducted eight prevalence surveys on myopia among children aged 3–18. In the study by Tsai et al. which collected and analyzed data from these eight surveys, the results consistently showed increasing trends in the prevalence of myopia across all age groups. The most recent survey revealed myopia rates of 92.90% and 90.34% among junior high and high school students, respectively [5].
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 18 print issues and online access
$259.00 per year
only $14.39 per issue
Learn more
Prices may be subject to local taxes which are calculated during checkout
References
Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123:1036–42. https://doi.org/10.1016/j.ophtha.2016.01.006.
Wu PC, Chuang MN, Choi J, Chen H, Wu G, Ohno-Matsui K, et al. Update in myopia and treatment strategy of atropine use in myopia control. Eye. 2019;33:3–13. https://doi.org/10.1038/s41433-018-0139-7.
Shahsuvaryan ML. Atropine: updates on myopia pharmacotherapy. Taiwan J Ophthalmol. 2022;14:225–9. https://doi.org/10.4103/tjo.TJO-D-22-00060.
Fang YT, Chou YJ, Pu C, Lin PJ, Liu TL, Huang N, et al. Prescription of atropine eye drops among children diagnosed with myopia in Taiwan from 2000 to 2007: a nationwide study. Eye. 2013;27:418–24. https://doi.org/10.1038/eye.2012.279.
Tsai TH, Liu YL, Ma IH, Su CC, Lin CW, Lin LL, et al. Evolution of the prevalence of myopia among Taiwanese schoolchildren: a review of survey data from 1983 through 2017. Ophthalmology. 2021;128:290–301. https://doi.org/10.1016/j.ophtha.2020.07.017.
Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, et al. Atropine for the treatment of childhood myopia. Ophthalmology. 2006;113:2285–91. https://doi.org/10.1016/j.ophtha.2006.05.062.
Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119:347–54. https://doi.org/10.1016/j.ophtha.2011.07.031.
Chang FC, Chiu CH, Chen PH, Chiang JT, Miao NF, Chuang HY, et al. Children’s use of mobile devices, smartphone addiction and parental mediation in Taiwan. Comput Hum Behav. 2019;93:25–32. https://doi.org/10.1016/j.chb.2018.11.048.
Asharlous A, Hashemi H, Yekta A, Riazifar A, Doostdar A, Sadri M, et al. The effect of cycloplegia on ocular alignment and AC/A ratio. J Ophthalmic Vis Res. 2024;19:82–87. https://doi.org/10.18502/jovr.v19i1.15442.
Alrasheed SH, Osman TM, Aljohani S, Alshammeri S. Clinical features of Sudanese patients presenting with binocular vision anomalies: a hospital-based study. J Med Life. 2023;16:1251–7. https://doi.org/10.25122/jml-2023-0132.
Syeda SI, Kumar R, Jayaseelan XC, Vijayaraghavan R. A comparative study to assess the accommodation and vergence relationship of myopia in indian adolescent. Ethiop J Health Sci. 2023;33:523–32. https://doi.org/10.4314/ejhs.v33i3.16.
Ma J, Yang X, Liu Z, Fu H, Fan S, Wang K, et al. The impact of vergence dysfunction on myopia control in children wearing defocus spectacle lenses. Clin Ophthalmol. 2024;18:799–807. https://doi.org/10.2147/OPTH.S453731.
Aman S, Guyton DL. Esotropia caused by low-dose atropine for rapidly progressive myopia in a 15-year-old boy. J AAPOS. 2025;29:104122. https://doi.org/10.1016/j.jaapos.2025.104122.
Wen Q, Fan TJ, Tian CL. Cytotoxicity of atropine to human corneal endothelial cells by inducing mitochondrion-dependent apoptosis. Exp Biol Med. 2016;241:1457–65. https://doi.org/10.1177/1535370216640931.
Acknowledgements
The authors used ChatGPT (OpenAI) for language refinement and improving the clarity of English expression during the preparation of the manuscript.
Author information
Authors and Affiliations
Department of Optometry, Chung Hwa University of Medical Technology, Tainan, Taiwan, ROC
Guan-Cheng Lin,Li-Te Yin&Kun-Shiang Chen
Authors
- Guan-Cheng Lin
View author publications
You can also search for this author inPubMedGoogle Scholar
- Li-Te Yin
View author publications
You can also search for this author inPubMedGoogle Scholar
- Kun-Shiang Chen
View author publications
You can also search for this author inPubMedGoogle Scholar
Contributions
GCL—Writing and review. LTY—Review. KSC—Review.
Corresponding author
Correspondence to Guan-Cheng Lin.
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lin, GC., Yin, LT. & Chen, KS. Rethinking the limitations of atropine in myopia control: new insights on binocular vision anomalies. Eye (2025). https://doi.org/10.1038/s41433-025-03864-5
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41433-025-03864-5
